Explore the mechanism of Huangqi Jiedu decoction in the treatment of breast cancer syndrome of Zheng-deficiency and toxic-incandescence based on network pharmacology and molecular docking technology
Objective To explore the mechanism of Huangqi Jiedu Decoction(HQJD)in the treatment of breast cancer with the syndrome of Zheng deficiency and toxic incandescence by network pharmacology and molecular docking technology.Methods The main active ingredients and targets of HQJD were screened through the traditional Chinese medicine(TCM)systematic pharmacology database and analysis platform.The relevant targets of breast cancer with the syndrome of Zheng-deficiency,toxic-incandescence were obtained using OMIM,GeneGards and Drugbank databases,and the relevant targets of HQJD for the treatment of breast cancer with the syndrome of Zheng-deficiency and toxic incandescence were obtained by intersection;The Cytoscape 3.9.1 software was used to build the protein protein interaction(PPI)network and the"drug active component target disease"network on the basis of String 11.0 database,and the core active components and core targets of HQJD in treating breast cancer with the syndrome of Zheng-deficiency and toxic-incandescence were inferred according to the topological parameters.gene ontology(GO)enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analysis were performed on core targets using R language;and molecular docking verification on the main active ingredients and core targets were conducted.Results 230 effective targets of active ingredients of HQJD were screened,and 15 467 active ingredients of breast cancer with syndrome of Zheng-deficiency/toxic-incandescence were obtained;217 intersection targets;GO function enrichment analysis showed that the treatment of HQJD for breast cancer with the syndrome of Zheng-deficiency and toxic-incandescence mainly involved oxidative stress and cytochemical stress;The enrichment analysis of KEGG pathway showed that HQJD treatment of breast cancer with the syndrome of Zheng-deficiency and toxic-incandescence was mainly related to phosphatidylinositol 3-protein kinase B(PI3K-Akt),interleukin-17(IL-17)and other signal pathways.The molecular docking results showed that the main active ingredients such as β-sitosterol,stigmasterol,luteolin had good binding ability with core targets.Conclusions HQJD has the characteristics of multi-component,multi target and multi pathway in the treatment of breast cancer with syndrome of Zheng-deficiency and toxic-incandescence,and its main mechanism may be related to PI3K-Akt,IL-17,P53 and other signal pathways.
Breast neoplasmsHuangqi Jiedu decoctionNetwork pharmacologyMolecular docking
万方数据
维普
